While the data looks good so far, the duo's treatment is behind a similar BioMarin therapy in the testing and approval process.
News & Analysis: BioMarin Pharmaceutical
Revenue is climbing at these biotech companies. And one of them is waiting for what could be an historic product approval.
The biotech is experiencing some disruption from the COVID-19 pandemic, but not enough to derail its growing momentum.
BMRN earnings call for the period ending March 31, 2020.
Is this a prime opportunity for investors to buy the gene therapy drugmaker?
These profitable and growing companies are conservative picks at good prices.
These biopharma stocks are taking a big hit because of the COVID-19 pandemic.
An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.
BioMarin's stock isn't escaping the marketwide sell-off. Savvy investors, though, may want to take advantage of this latest decline in the drugmaker's shares.
Even healthcare companies can't escape the overall market downturn.